Monacolin K health claims could carry safety warnings

By Annie Harrison-Dunn contact

- Last updated on GMT

“It was agreed with the member states that such an approach would also ensure better protection of the consumer," says Commission
“It was agreed with the member states that such an approach would also ensure better protection of the consumer," says Commission

Related tags: Red yeast rice, Statin

Accompanying warnings are being considered for monacolin K health claims after a number of EU member states raised safety concerns.

A spokesperson for the European Commission told us the possibility of introducing certain warning statements for the health claims was discussed in its last two working groups held in January and March.

“It was agreed with the member states that such an approach would also ensure better protection of the consumer.”

The spokesperson said it would be premature to give more details on the nature of the statements and a timeline could not yet be set.

Monacolin K is an active compound naturally present in red yeast rice, which is chemically identical to cholesterol statin drugs like lovastatin and has therefore been hailed as a food alternative to medication.

A general function article 13.1 health claim was authorised by the European Foods Safety Authority (EFSA) in 2011. It stated: “Monacolin K from red yeast rice contributes to the maintenance of normal blood cholesterol concentrations.”

A disease risk factor reduction article 14 health claim was authorised by EFSA in 2013​. It stated: “A combination of artichoke leaf dry extract standardised in caffeoylquinic acids, monacolin K in red yeast rice, sugar-cane derived policosanols, OPC from French maritime pine bark, garlic dry extract standardised in allicin, d-α-tocopheryl hydrogen succinate, riboflavin and inositol hexanicotinate reduces blood LDL-cholesterol concentrations. High LDL-cholesterol is a risk factor in the development of coronary heart disease.”

However last year the French Agency for Food, Environmental and Occupational Health and Safety (ANSES) issued a warning​ against red yeast rice.

After calling for input on its safety back in 2013, it revealed there had been 25 cases of illness linked to the botanical since 2009, mostly related to muscle and liver health issues. In its warning it said: “The Agency considers that use of this kind of food supplement containing monacolins may expose consumers to a health risk – especially individuals who are particularly susceptible due to genetic predispositions, pathologies, ongoing treatments, etc. ANSES therefore recommends seeking medical advice before taking these products.”

It was highlighted that statin intake from all sources could be taken into account, as well as an individual’s tolerance.

The ingredient’s status as drug or supplement has also varied with monacolin traded in both the pharma and food spheres. This status often depends on the monacolin content, with this dosage distinction differing across member states.

Both ANSES and industry have called for greater clarity on an EU level.

Related news

Show more

Related products

show more

Robuvit® Boosts Recovery Following Surgery

Robuvit® Boosts Recovery Following Surgery

Horphag Research | 22-Jun-2020 | Clinical Study

New research found Robuvit® French oak extract improves general health, mood and social functioning of post-surgery patients. Robuvit®’s antioxidative...

Sugar Reduction for Plant-based Protein Beverages

Sugar Reduction for Plant-based Protein Beverages

SweeGen Inc. | 17-Jun-2020 | Product Brochure

Creating protein beverages with less sugar and no artificial sweeteners is key to reaching today’s label conscious consumers. Our Bestevia® Taste Solutions...

Related suppliers

1 comment

prescription drug

Posted by Stefan,

this ingredient is definitely the same as a prescription drug with considerable side effects.
It has nothing to do with a Food Supplement
warnings are the least to be necessary for such products

Report abuse

Follow us

Products

View more

Webinars